Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Classical hematology 1

Conditions

Leukemia, Myeloid, Acute 13Myelodysplastic Syndromes 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Hodgkin Disease 7Leukemia, Biphenotypic, Acute 5Burkitt Lymphoma 5Lymphoma, Non-Hodgkin 4Hematologic Neoplasms 4Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Neuroblastoma 3Neoplasms 3Leukemia, Myelomonocytic, Chronic 3Rhabdomyosarcoma 2Myeloproliferative Disorders 2Lymphoma, Mantle-Cell 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2Lymphoma 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Leukemia 2Teratoma 1Solid Tumors 1Sarcoma 1Recurrence 1Myelodysplastic-Myeloproliferative Diseases 1Multi-centric Castleman's Disease 1Malignant mesenchymal tumor 1Macular dystrophy, corneal type 1 1Lymphoproliferative Disorders 1Lymphoma, Large-Cell, Anaplastic 1

Interventions

Injections 2Gemtuzumab 2Decitabine 2Cytarabine 2fludarabine phosphate 1Idarubicin 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Daunorubicin 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Myelomonocytic, Acute × Filgrastim × 90 days × Clear all
NCT00801489 2026-03-30

Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

M.D. Anderson Cancer Center

Phase 2 Recruiting
270 enrolled
Classical hematologyOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Leukemia, Myelomonocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡